ARTIMPLANT YEAR-END REPORT JANUARY – DECEMBER 2007

Västra Frölunda, Sweden, February 22, 2008, 08:45 CET (GMT+1)

• Net revenue for the fourth quarter increased to SEK 5.0 million (1.6) and for the year to SEK 16.3 million (5.5)*
• The net loss for the fourth quarter improved to SEK -2.1 million (-9.5) and for the year to SEK 13.4 million (-56.0)
• The net loss for the year, excluding non-recurring items, improved to SEK 11.8 million (-38.9)
• Earnings per share for the year improved to SEK -0.23 (-0.95)
• Sales of Artelon® CMC Spacer amounted to approximately 3,900 (2,750) units, of which approximately 1,100 (1,050) were during the fourth quarter
• Over 6,000 patients were treated with Artelon® implants up to and including 2007
• Artelon® Tissue Reinforcement was granted FDA clearance for several new indications
• FDA clearance for two new Spacer products
• An agreement was signed with Small Bone Innovations for new resurfacing indications for the hand and wrist

Artimplant will hold a telephone conference on this report on February 22, 2008 at 11am, Central European Time (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year